373 related articles for article (PubMed ID: 27982416)
1. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
Schmitz N; de Leval L
Br J Haematol; 2017 Mar; 176(6):851-866. PubMed ID: 27982416
[TBL] [Abstract][Full Text] [Related]
2. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S; Yoshida S; Kato K; Choi I; Imamura Y; Kohno K; Henzan H; Tanimoto K; Ogawa R; Suehiro Y; Miyamoto T; Eto T; Ohshima K; Akashi K; Iwasaki H;
Int J Hematol; 2020 Jul; 112(1):74-83. PubMed ID: 32297159
[TBL] [Abstract][Full Text] [Related]
3. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
4. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
[TBL] [Abstract][Full Text] [Related]
5. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
7. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
8. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
10. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
[TBL] [Abstract][Full Text] [Related]
11. How to Sequence Therapies in Peripheral T Cell Lymphoma.
Wudhikarn K; Bennani NN
Curr Treat Options Oncol; 2021 Jul; 22(9):74. PubMed ID: 34213653
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Kawata T; Mizuta S; Ago H; Chou T; Yamane T; Uchiyama H; Oyake T; Miura K; Saito B; Taji H; Nakamae H; Miyamoto T; Fukuda T; Kanda J; Atsuta Y; Suzuki R
Int J Hematol; 2019 Feb; 109(2):175-186. PubMed ID: 30430419
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.
Mohammed Saleh MF; Kotb A; Abdallah GEM; Muhsen IN; El Fakih R; Aljurf M
Curr Oncol; 2021 Dec; 28(6):5480-5498. PubMed ID: 34940095
[TBL] [Abstract][Full Text] [Related]
14. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.
de Leval L; Gisselbrecht C; Gaulard P
Br J Haematol; 2010 Mar; 148(5):673-89. PubMed ID: 19961485
[TBL] [Abstract][Full Text] [Related]
15. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
Franco CM; Popplewell LL; Horwitz SM
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
[TBL] [Abstract][Full Text] [Related]
17. Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma.
Moskowitz AJ
J Oncol Pract; 2019 Mar; 15(3):137-143. PubMed ID: 30861367
[TBL] [Abstract][Full Text] [Related]
18. Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy.
Kallam A; Armitage JO
Expert Rev Hematol; 2020 Jul; 13(7):745-753. PubMed ID: 32478625
[TBL] [Abstract][Full Text] [Related]
19. [Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma].
Couronné L; Bastard C; Gaulard P; Hermine O; Bernard O
Med Sci (Paris); 2015 Oct; 31(10):841-52. PubMed ID: 26481023
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
